¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ ½ÃÀå
Nontuberculous Mycobacterial Infections
»óǰÄÚµå : 1794524
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 279 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ ½ÃÀåÀº 2030³â±îÁö 183¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 140¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 183¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ClarithromycinÀº CAGR 5.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 71¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Azithromycin ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 38¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ½ÃÀåÀº 2024³â¿¡ 38¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 38¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.8%¿Í 3.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºñ°áÇÙ¼º Ç×»ê±Õ(NTM)ÀÌ ÀÓ»óÀûÀ¸·Î ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

ºñ°áÇÙ¼º Ç×»ê±Õ¿¡ ÀÇÇÑ °¨¿°Àº ±â°üÁöÈ®ÀåÁõ, COPD, ³¶Æ÷¼º ¼¶À¯Áõ µî ¸¸¼ºÆóÁúȯ ȯÀÚ¿¡¼­ È®ÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ ¼¼±ÕÀº Åä¾ç, ¼ö°è, »ý¹°¸·¿¡ Á¸ÀçÇϸç Áö¼ÓÀû À̰í Ä¡·á°¡ ¾î·Á¿î Æó °¨¿°À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. °íÇØ»óµµ ¿µ»ó Áø´Ü°ú °´´ã¹è¾çÀÌ ºó¹øÇÏ°Ô ½ÃÇàµÇ¸é¼­ È£Èí±â Àü¹®ÀÇÀÇ ÀνÄÀÌ ³ô¾ÆÁ® Àü ¼¼°è¿¡¼­ È®Áø Áø´ÜÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

NTM °¨¿°Àº ÇǺÎ, ¿¬ºÎÁ¶Á÷, ¸²ÇÁÀý¿¡µµ ¹ß»ýÇϸç, ¸é¿ª °áÇÌ È¯ÀÚ¿¡¼­´Â ÆÄÁ¾ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿øÀÎ ºÒ¸íÀÇ È£Èí±â Áõ»óÀÌ ÀÖ°í CT ½ºÄµ¿¡¼­ °áÀý¼º ¶Ç´Â ±â°üÁö È®À强 º¯È­°¡ Áö¼ÓµÇ´Â ȯÀÚ¸¦ ÀǽÉÇ϶ó´Â ¾÷µ¥ÀÌÆ®µÈ °¡À̵å¶óÀÎÀ» ÅëÇØ ÀÓ»óÀû ÀνÄÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °æ°¢½É °íÁ¶·Î ÀÎÇØ º¸´Ù ü°èÀûÀÎ °ËÁø ¹× ÀÓ»ó °Ë»ç¸¦ ÃßÁøÇÏ¿© ½ÇÁ¦ ¹ßº´·üÀÌ ³ô¾ÆÁ®µµ °¨¿°·üÀº »ó½ÂÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áø´Ü°ú Ä¡·áÀÇ Çõ½ÅÀÌ È¯ÀÚ °á°ú¸¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

NTMÀÇ Áø´Ü¹ýÀº ±âÁ¸ÀÇ ¹è¾ç¿¡ ±â¹ÝÇÑ ¹æ¹ý¿¡¼­ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. PCR ¹× ¶óÀÎ ÇÁ·Îºê ºÐ¼®°ú °°Àº ºÐÀÚ ºÐ¼®Àº º¸´Ù ½Å¼ÓÇÑ ±ÕÁ¾ ½Äº° ¹× Ç×±ÕÁ¦ ³»¼º °ËÃâÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ³ôÀº Á¤È®µµ·Î ÀÎÇØ ÀÓ»óÀÇ´Â Ä¡·á Ãʱ⠴ܰ迡¼­ Ç×±ÕÁ¦ ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á ¼º°ø·üÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¿Í ÷´Ü ¿µ»ó Áø´Ü ±â¼úÀÇ Á¶»ç´Â ÀÓ»ó °ü¸®ÀÇ Áß¿äÇÑ °úÁ¦ÀΠȰµ¿¼º °¨¿°°ú ÄÝ·Î´Ï Çü¼ºÀÇ °¨º°¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÇöÀç Ä¡·á´Â ¿©·¯ °¡Áö Ç׸¶ÀÌÄÚ¹ÚÅ׸®¾Æ ¾à¹°À» º´¿ëÇÏ¿© 12°³¿ù ÀÌ»ó Àå±âÀûÀ¸·Î Åõ¿©ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÈíÀÔ¿ë ¾Æ¹ÌÄ«½Å ¸®Æ÷Á» Çöʾ×À̳ª ¿Á»çÁ¹¸®µð³í°è Ç×±ÕÁ¦¿Í °°Àº »õ·Î¿î ¾à¹°Àº Àü½Å µ¶¼ºÀ» ÁÙÀΠǥÀû Ä¡·áÁ¦¸¦ Á¦°øÇÕ´Ï´Ù. ±âµµÈ®º¸ÀåÄ¡, Æó ÀçȰġ·á µîÀÇ º¸Á¶Ä¡·á´Â Æó±â´É°ú Ä¡·á ¼øÀÀµµ¸¦ µ½½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­´Â ¼÷ÁÖÀÇ ¹ÝÀÀÀ» ³ôÀÌ°í ¹ÚÅ׸®¾Æ ºÎ´ãÀ» ÁÙÀÌ´Â ¸é¿ª Á¶ÀýÁ¦¸¦ ½ÃÇèÇϰí ÀÖÀ¸¸ç, À¯¸Á Ãʱ⠴ܰèÀÇ °á°ú¸¦ ¾ò¾ú½À´Ï´Ù.

¾î¶² Ä¡·á ¸ðµ¨°ú °ü¸® Àü·«ÀÌ µîÀåÇϰí Àִ°¡?

NTM °¨¿°ÁõÀÇ °ü¸®´Â Æó Àü¹®ÀÇ, °¨¿° Àü¹®ÀÇ, ¿µ»óÀÇÇаú Àü¹®ÀÇ, ¾à»ç µî ´ÙÇÐÁ¦ Áø·áÆÀ¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Á¾ÇÕÀûÀÎ Äɾî Çãºê´Â Áø´Ü, Ä¡·á ½ÃÀÛ, ¾à¹° »óÈ£ÀÛ¿ë ¹× ºÎÀÛ¿ë ¸ð´ÏÅ͸µ, ¼øÀÀµµ Áö¿ø µîÀ» ÅëÇÕÀûÀ¸·Î ¼öÇàÇÕ´Ï´Ù. ¿ø°ÝÀÇ·á Åø¿Í µðÁöÅÐ ¾Ë¸²Àº Àå±âÀûÀÎ Ä¡·á ¼øÀÀµµ¸¦ ¸ð´ÏÅ͸µÇÏ°í ºÎÀÛ¿ëÀ» ¿ø°ÝÀ¸·Î ÃßÀûÇÏ´Â µ¥¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ȯÀÚ ±³À° ¹× Áö¿ø ±×·ìÀº Ä¡·áÀÇ Æ²¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Ç÷§ÆûÀ» ÅëÇÑ Áö¼ÓÀûÀΠȯÀÚ Âü¿©´Â Àå±â Ä¡·á¿¡ µû¸¥ Á¤¼­Àû, ÈĹæ Áö¿øÀû ¹®Á¦¸¦ °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº Ä¡·á °á°ú, ±ÕÁ¾ ºÐÆ÷, Áö¿ª ¿ªÇп¡ °üÇÑ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â NTM¿¡ ƯȭµÈ µî·ÏÀ» °³¹ßÇÏ¿© º¸´Ù Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤°ú º¥Ä¡¸¶Å·À» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

ºñ°áÇÙ¼º Ç×»ê±ÕÁõ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

ƯÈ÷ °í·ÉÈ­ ¹× ¸é¿ª·ÂÀÌ ÀúÇÏµÈ »ç¶÷µé »çÀÌ¿¡¼­ NTM °¨¿°ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ȯÀÚÃþ°ú ÀÓ»óÀû ÀνÄÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ºÐÀÚÁø´ÜÇÐÀÇ ¹ßÀüÀ¸·Î º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ ±ÕÁ¾ ½Äº°°ú ³»¼º ÇÁ·ÎÆÄÀϸµÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. »õ·Î¿î Ç׸¶ÀÌÄÚ¹ÚÅ׸®¾Æ ¾à¹°°ú ÈíÀÔ Àü´Þ ½Ã½ºÅÛÀÇ µµÀÔÀ¸·Î Ç¥ÁØ ¿ä¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀÌ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ ¼øÀÀµµ ÅøÀÌ Áö¿øÇÏ´Â ´ÙÇÐÁ¦Àû Ä¡·á ¸ðµ¨ÀÇ ÃâÇöÀ¸·Î Àå±âÀûÀÎ Ä¡·á ¼º°ø·üÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ȯÀÚ µî·ÏÀÇ Çü¼º°ú NTMÀÇ ¿ªÇÐ ¹× Ä¡·á¿¡ ´ëÇÑ ¿¬±¸ÀÇ ¹ßÀüÀº Ä¡·áÀÇ Çõ½Å°ú ÀÇ·áÁøÀÇ º£½ºÆ® ÇÁ·¢Æ¼½º äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾àÁ¦ À¯Çü(Clarithromycin, Azithromycin, Rifampin, Rifabutin, ±âŸ ¾àÁ¦ À¯Çü), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Äõ¸® ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nontuberculous Mycobacterial Infections Market to Reach US$18.3 Billion by 2030

The global market for Nontuberculous Mycobacterial Infections estimated at US$14.0 Billion in the year 2024, is expected to reach US$18.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Clarithromycin, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Azithromycin segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 8.4% CAGR

The Nontuberculous Mycobacterial Infections market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Nontuberculous Mycobacterial Infections Market - Key Trends & Drivers Summarized

Why Are Nontuberculous Mycobacteria (NTM) Gaining Clinical Attention?

Infections caused by nontuberculous mycobacteria have become a growing concern due to increasing identification in patients with chronic lung conditions, such as bronchiectasis, COPD, or cystic fibrosis. These environmental bacteria are found in soil, water systems, and biofilms and can cause persistent, difficult-to-treat pulmonary infections. Increased awareness among pulmonologists, coupled with more frequent use of high-resolution imaging and sputum cultures, has led to a rise in confirmed diagnoses globally.

NTM infections can also occur in skin and soft tissue, lymph nodes, and disseminated in immunocompromised individuals. Clinical recognition has improved through updated guidelines that encourage suspicion in patients with unexplained respiratory symptoms and persistent nodular or bronchiectatic changes on CT scans. This heightened vigilance has driven more systematic screening and laboratory testing, making infection rates appear to rise even as actual incidence increases.

How Are Diagnostic and Treatment Innovations Improving Patient Outcomes?

Diagnostic methods for NTM are evolving beyond traditional culture-based techniques. Molecular assays, such as PCR and line probe assays, enable faster species identification and antimicrobial resistance detection. This precision allows clinicians to tailor antibiotic regimens early in therapy, improving treatment success. Research into novel biomarkers and advanced imaging techniques is helping differentiate active infection from colonization, addressing a key challenge in clinical management.

Therapeutic approaches now combine multiple antimycobacterial agents administered for long durations, often exceeding 12 months. Newer drugs-such as inhaled amikacin liposome suspension and oxazolidinones-offer targeted therapy with reduced systemic toxicity. Adjunct treatments, including airway clearance devices and pulmonary rehabilitation, support lung function and treatment adherence. Clinical trials are testing immunomodulatory agents to boost host response and reduce bacterial burden, with promising early-stage results.

What Care Models and Management Strategies Are Emerging?

Management of NTM infections increasingly relies on multidisciplinary care teams that include pulmonologists, infectious disease specialists, radiologists, and pharmacists. Comprehensive care hubs offer coordinated diagnostics, treatment initiation, monitoring of drug interactions, side effects, and adherence support. Telehealth tools and digital reminders are also being used to monitor long-term treatment compliance and track adverse effects remotely.

Patient education and support groups are gaining importance in treatment frameworks. Sustained patient engagement through digital platforms helps manage the emotional and logistical challenges of prolonged therapy. Health systems are beginning to develop NTM-specific registries that collect data on treatment outcomes, species distribution, and regional epidemiology, enabling more informed decision-making and benchmarking.

Growth in the nontuberculous mycobacterial infections market is driven by several factors.

Increasing prevalence of NTM infections, especially among aging and immunocompromised populations, is expanding patient pools and clinical awareness. Advances in molecular diagnostics are enabling faster and more accurate species identification and resistance profiling. Introduction of novel antimycobacterial drugs and inhaled delivery systems is offering alternatives to standard therapies. Emergence of multidisciplinary care models supported by telehealth and digital adherence tools is improving long-term treatment success. Finally, formation of patient registries and growing research into NTM epidemiology and therapeutics are fostering treatment innovation and adoption of best practices by healthcare providers.

SCOPE OF STUDY:

The report analyzes the Nontuberculous Mycobacterial Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â